"Narcotic Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents inhibiting the effect of narcotics on the central nervous system.
| Descriptor ID |
D009292
|
| MeSH Number(s) |
D27.505.696.543 D27.505.696.663.850.512 D27.505.954.427.550
|
| Concept/Terms |
Narcotic Antagonists- Narcotic Antagonists
- Antagonists, Narcotic
- Opioid Receptor Antagonists
- Antagonists, Opioid Receptor
- Receptor Antagonists, Opioid
- Opioid Antagonists
- Antagonists, Opioid
|
Below are MeSH descriptors whose meaning is more general than "Narcotic Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Narcotic Antagonists".
This graph shows the total number of publications written about "Narcotic Antagonists" by people in this website by year, and whether "Narcotic Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2014 | 2 | 0 | 2 |
| 2017 | 9 | 3 | 12 |
| 2018 | 16 | 11 | 27 |
| 2019 | 6 | 2 | 8 |
| 2020 | 2 | 1 | 3 |
| 2021 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Narcotic Antagonists" by people in Profiles.
-
Increasing Short- and Long-Term Buprenorphine Treatment Capacity: Providing Waiver Training for Medical Students. Acad Med. 2022 02 01; 97(2):182-187.
-
A Telemedicine Buprenorphine Clinic to Serve New York City: Initial Evaluation of the NYC Public Hospital System's Initiative to Expand Treatment Access During the COVID-19 Pandemic. J Addict Med. 2022 Jan-Feb 01; 16(1):e40-e43.
-
The impact of COVID-19 on healthcare delivery for people who use opioids: a scoping review. Subst Abuse Treat Prev Policy. 2021 08 09; 16(1):60.
-
Willingness to use a wearable device capable of detecting and reversing overdose among people who use opioids in Philadelphia. Harm Reduct J. 2021 07 23; 18(1):75.
-
Expanding Mail-Based Distribution of Drug-Related Harm Reduction Supplies Amid COVID-19 and Beyond. Am J Public Health. 2021 06; 111(6):1013-1017.
-
Opioid use disorder and COVID-19: Implications for policy and practice. JAAPA. 2021 Jun 01; 34(6):1-4.
-
Are opioid receptor antagonists adequate for "Opioid" overdose in a changing reality? J Clin Pharm Ther. 2021 Aug; 46(4):861-866.
-
Assessment of Filled Buprenorphine Prescriptions for Opioid Use Disorder During the Coronavirus Disease 2019 Pandemic. JAMA Intern Med. 2021 04 01; 181(4):562-565.
-
Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic. Am J Health Syst Pharm. 2021 03 18; 78(7):613-618.
-
A free mailed naloxone program in Philadelphia amidst the COVID-19 pandemic. Int J Drug Policy. 2021 08; 94:103199.